Quantcast
Last updated on April 18, 2014 at 10:39 EDT

Latest SLC5A2 Stories

2014-01-29 16:29:02

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/2qlc2k/lexicons_lx4211) has announced the addition of the "Lexicon's LX4211 - FDA canagliflozin decision is key bellweather" [http://www.researchandmarkets.com/research/2qlc2k/lexicons_lx4211 ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) LX4211 is part of a new class of type 2 diabetes agents that inhibit the SGLT2...

2013-10-01 08:29:48

THE WOODLANDS, Texas, Oct. 1, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that LX4211, a first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), successfully met the primary endpoint of reducing post-prandial glucose, in a study of patients with type 2 diabetes and moderate to severe renal impairment. Reducing elevated post-prandial glucose, high blood sugar levels after meals, is a key objective of diabetes...

2013-07-30 08:32:28

Conference Call and Webcast at 11:00 a.m. Eastern Time THE WOODLANDS, Texas, July 30, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2013. "We have continued to advance multiple programs in our clinical pipeline, most notably completing...

2013-06-24 08:28:10

LX2761 Acts Locally in GI Tract to Inhibit Sodium Glucose Transporter 1 THE WOODLANDS, Texas, June 24, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented the first publication of data on LX2761 at the 73(rd) Scientific Sessions of the American Diabetes Association (ADA) in Chicago, on June 23, 2013. David Powell, M.D., Lexicon's senior vice president of...

2013-05-10 08:24:10

Conference Call and Webcast at 11:00 a.m. Eastern Time THE WOODLANDS, Texas, May 10, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2013. "In the first quarter of 2013, we continued to progress our clinical pipeline on multiple fronts. Most...

2012-11-06 12:27:08

THE WOODLANDS, Texas, Nov. 6, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California. The oral presentation is being delivered by Dr. Julio Rosenstock, Director of the Dallas Diabetes and...

2012-09-25 02:29:13

RARITAN, N.J., Sept. 25, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) will present new Phase 3 data results evaluating canagliflozin, an investigational sodium glucose co-transporter 2 (SGLT2) inhibitor, in adult patients with type 2 diabetes at the upcoming annual meeting of the European Association for the Study of Diabetes (EASD), from October 1-5, 2012 in Berlin, Germany. "The data we will present at EASD are the latest results from our...